HONG KONG: Sirnaomics has announced an initial public offering (IPO) in Hong Kong. The company is offering 7.54 million shares at HK$65.9-HK$72.7 per share.

Sirnaomics Ltd is the first and only clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both China and the U.S.

It will start its public offering on Monday and trading is expected to begin December 30, 2021 the company said.

Kunming Jiashiqing and Innoforce Pharmaceuticals have been introduced as the cornerstone investors, according to the statement.

China International Capital Corporation Hong Kong Securities Ltd. is the sole sponsor, joint global coordinator and joint bookrunner. Hongkong and Shanghai Banking Corp., Nomura International (Hong Kong) Ltd., China Merchants Securities (HK) Co. and China PA Securities (Hong Kong) Co. are the joint global coordinators and bookrunners.

Sirnaomics is a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China.

The Company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need.

The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China.

The company is supported by funding from institutional investors and corporate partnerships. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. www.sirnaomics.com